|
122 Companies |
|
195 Products |
|
195 Products |
|
116 Mechanisms of Action |
|
3 Trials |
|
2333 News |
|
| «12...2829303132333435363738...4647» |
- ||||||| Trial completion: Effectiveness of an Electronic Training Program for Orienting and Interpreting [18F]Flutemetamol Positron Emission Tomography (PET) Images (clinicaltrials.gov) - Oct 23, 2013
P3, N=276, Completed, Sponsor: GE Healthcare
Active, not recruiting --> Completed
- | New P4 trial: VENUS: Neuroprotection by Tocotrienols in Type 1 and Type 2 Diabetes Mellitus (clinicaltrials.gov) - Oct 23, 2013
P4, N=300, Recruiting, Sponsor: University of Science Malaysia
- || encenicline (EVP-6124) / Forum Pharmaceuticals, Mitsubishi Tanabe
New P3 trial: Study of the Safety and Effectiveness of Two Doses of Investigational Study Drug EVP-6124 in Subjects With Alzheimer's Disease (clinicaltrials.gov) - Oct 23, 2013
P3, N=790, Recruiting, Sponsor: FORUM Pharmaceuticals Inc
- || encenicline (EVP-6124) / Forum Pharmaceuticals, Mitsubishi Tanabe
New P3 trial: Study of the Safety and Effectiveness of Two Doses of Investigational Study Drug EVP-6124 in Subjects With Alzheimer's Disease (clinicaltrials.gov) - Oct 23, 2013
P3, N=790, Recruiting, Sponsor: FORUM Pharmaceuticals Inc
- | encenicline (EVP-6124) / Forum Pharmaceuticals, Mitsubishi Tanabe
Enrollment open: Study of the Safety and Effectiveness of Two Doses of Investigational Study Drug EVP-6124 in Subjects With Alzheimer's Disease (clinicaltrials.gov) - Oct 23, 2013
P3, N=790, Recruiting, Sponsor: FORUM Pharmaceuticals Inc
Active, not recruiting --> Completed Not yet recruiting --> Recruiting
- | encenicline (EVP-6124) / Forum Pharmaceuticals, Mitsubishi Tanabe
Enrollment open: Study of the Safety and Effectiveness of Two Doses of Investigational Study Drug EVP-6124 in Subjects With Alzheimer's Disease (clinicaltrials.gov) - Oct 23, 2013
P3, N=790, Recruiting, Sponsor: FORUM Pharmaceuticals Inc
Not yet recruiting --> Recruiting Not yet recruiting --> Recruiting
- Enrollment open: Differential Effects of Various Anesthetic Agents on Cognitive Function in Patients With Alzheimer's Disease (clinicaltrials.gov) - Oct 22, 2013
P=N/A, N=100, Recruiting, Sponsor: Massachusetts General Hospital
Not yet recruiting --> Recruiting Not yet recruiting --> Recruiting
- |||| VI-1121 / IEH Biopharma
Trial completion: VI-1121 for the Treatment Alzheimer's Disease (clinicaltrials.gov) - Oct 22, 2013
P2, N=61, Completed, Sponsor: VIVUS, Inc.
Not yet recruiting --> Recruiting Active, not recruiting --> Completed
- |||| itanapraced (CHF-5074) / CereSpir
Trial completion: CT04 POLEP: Evaluation of Safety & Tolerability of Multiple Dose Regimens of CHF 5074 and Exploration of Effects on Potential Markers of Clinical Efficacy in Patients With Mild Cognitive Impairment - Prolonged Open Label Extension Phase (clinicaltrials.gov) - Oct 22, 2013
P2, N=51, Completed, Sponsor: Chiesi Pharmaceuticals Inc.
Active, not recruiting --> Completed Active, not recruiting --> Completed
- Enrollment open: Effectiveness of a Multifactorial Intervention on Frailty (clinicaltrials.gov) - Oct 20, 2013
P=N/A, N=320, Recruiting, Sponsor: Jordi Gol i Gurina Foundation
Active, not recruiting --> Completed Not yet recruiting --> Recruiting
- sembragiline (RO4602522) / Roche, Evotec
Enrollment change: A Study of RO4602522 in Patients With Alzheimer Disease and in Healthy Volunteers (clinicaltrials.gov) - Oct 20, 2013
P1, N=17, Completed, Sponsor: Hoffmann-La Roche
Not yet recruiting --> Recruiting N=24 --> 17
- | sembragiline (RO4602522) / Roche, Evotec
Trial completion: A Study of RO4602522 in Patients With Alzheimer Disease and in Healthy Volunteers (clinicaltrials.gov) - Oct 20, 2013
P1, N=17, Completed, Sponsor: Hoffmann-La Roche
N=24 --> 17 Recruiting --> Completed
- | New P2 trial, Metastases: A Pilot Study of an RCT to Improve Infection Management in Advanced Dementia (clinicaltrials.gov) - Oct 17, 2013
P2, N=60, Not yet recruiting, Sponsor: Hebrew Rehabilitation Center, Boston
- modafinil / Generic mfg.
New P4 trial: Targeting Circadian and Cognitive Dysfunction in Bipolar Disorder With Modafinil (clinicaltrials.gov) - Oct 16, 2013
P4, N=48, Recruiting, Sponsor: Mount Sinai School of Medicine
- metformin / Generic mfg.
Biomarker, New P2 trial: Effect of Insulin Sensitizer Metformin on AD Biomarkers (clinicaltrials.gov) - Oct 16, 2013
P2, N=30, Recruiting, Sponsor: University of Pennsylvania
- Trial completion: Phase II Study of the Efficacy of Peptide T in HIV-Positive Individuals With Cognitive Impairment. (clinicaltrials.gov) - Oct 16, 2013
P2, N=100, Completed, Sponsor: National Institute of Mental Health (NIMH)
Recruiting --> Completed Active, not recruiting --> Completed
- Vyvanse (lisdexamfetamine) / Shionogi, Takeda
Enrollment closed: Attention & Memory Impairments in Menopausal Women (clinicaltrials.gov) - Oct 13, 2013
P4, N=34, Active, not recruiting, Sponsor: University of Pennsylvania
Active, not recruiting --> Completed Recruiting --> Active, not recruiting
- Trial completion: DLA: Dynamic Light Application to Prevent ICU Acquired Delirium (clinicaltrials.gov) - Oct 13, 2013
P=N/A, N=1000, Completed, Sponsor: Jeroen Bosch Ziekenhuis
Recruiting --> Active, not recruiting Recruiting --> Completed
- |||| PF-02545920 / Pfizer
Enrollment open: Study Evaluating The Safety, Tolerability And Brain Function Of 2 Doses Of PF-0254920 In Subjects With Early Huntington's Disease (clinicaltrials.gov) - Oct 10, 2013
P2, N=56, Recruiting, Sponsor: Pfizer
Recruiting --> Completed Not yet recruiting --> Recruiting
- choline alfoscerate / Generic mfg.
Trial completion: GLITTER: The Efficacy of Gliatiline® on Post-stroke Patients With Vascular Cognitive Impairment no Dementia (clinicaltrials.gov) - Oct 10, 2013
P4, N=222, Completed, Sponsor: Seoul National University Hospital
Not yet recruiting --> Recruiting Recruiting --> Completed
- ||||| LMTX (hydromethylthionine) / TauRx
Trial initiation date: Safety and Efficacy Study Evaluating TRx0237 in Subjects With Behavioral Variant Frontotemporal Dementia (bvFTD) (clinicaltrials.gov) - Oct 8, 2013
P3, N=180, Recruiting, Sponsor: TauRx Therapeutics Ltd
Recruiting --> Completed Initiation date: Feb 2013 --> Aug 2013
- ||||| LMTX (hydromethylthionine) / TauRx
Enrollment change: Safety and Efficacy Study Evaluating TRx0237 in Subjects With Mild Alzheimer's Disease (clinicaltrials.gov) - Oct 8, 2013
P3, N=700, Recruiting, Sponsor: TauRx Therapeutics Ltd
Initiation date: Feb 2013 --> Aug 2013 N=500 --> 700
- New P1 trial: Enhancing Spatial Navigation Using Non-Invasive Brain Stimulation (clinicaltrials.gov) - Oct 7, 2013
P1, N=100, Recruiting, Sponsor: Department of Veterans Affairs
- | clonidine / Generic mfg.
New P2 trial: LUCID: The Oslo Study of Clonidine in Elderly Patients With Delirium (clinicaltrials.gov) - Oct 6, 2013
P2, N=100, Recruiting, Sponsor: Oslo University Hospital
- Enrollment open: 2-StaLi: Cognitive Outcome After Two-stage Liver-Operation (clinicaltrials.gov) - Oct 6, 2013
P=N/A, N=20, Recruiting, Sponsor: Charite University, Berlin, Germany
N=500 --> 700 Not yet recruiting --> Recruiting
- |||||||||| idalopirdine (Lu AE58054) / Otsuka, Eli Lilly, Denovo
New P3 trial: STARSHINE: Study of Idalopirdine in Patients With Mild - Moderate Alzheimer's Disease Treated With Donepezil (clinicaltrials.gov) - Oct 4, 2013
P3, N=930, Recruiting, Sponsor: H. Lundbeck A/S
- Enrollment open: Impact of Emotional Mimicry and Oxytocin on Frontotemporal Dementia (clinicaltrials.gov) - Oct 3, 2013
P2, N=72, Recruiting, Sponsor: Lawson Health Research Institute
Not yet recruiting --> Recruiting Not yet recruiting --> Recruiting
- |||||||||| verubecestat (MK-8931) / Merck (MSD)
New P3 trial: APECS: Efficacy and Safety Trial of Verubecestat (MK-8931) in Participants With Prodromal Alzheimer's Disease (MK-8931-019) (clinicaltrials.gov) - Sep 29, 2013
P3, N=1500, Recruiting, Sponsor: Merck Sharp & Dohme Corp.
- ||| MK-7622 / Merck (MSD)
Enrollment change: Efficacy and Safety of MK-7622 as Adjunct Therapy in Participants With Alzheimer's Disease (MK-7622-012) (clinicaltrials.gov) - Sep 29, 2013
P2a, N=830, Recruiting, Sponsor: Merck Sharp & Dohme Corp.
Not yet recruiting --> Recruiting N=640 --> 830
- Trial initiation date: Effect of CPAP on Postoperative Delirium (clinicaltrials.gov) - Sep 26, 2013
P=N/A, N=130, Recruiting, Sponsor: Duke University
N=640 --> 830 Initiation date: Mar 2013 --> Jun 2013
- Enrollment open: Effect of CPAP on Postoperative Delirium (clinicaltrials.gov) - Sep 26, 2013
P=N/A, N=130, Recruiting, Sponsor: Duke University
Initiation date: Mar 2013 --> Jun 2013 Not yet recruiting --> Recruiting
- Enrollment open: CAPHA: Central Auditory Processing and the Use of Hearing Aids (clinicaltrials.gov) - Sep 24, 2013
P=N/A, N=56, Recruiting, Sponsor: Jong Woo Chung
Not yet recruiting --> Recruiting Not yet recruiting --> Recruiting
- || elenbecestat (E2609) / Eisai, Biogen
Enrollment change: Evaluation of E2609 in Subjects With Mild Cognitive Impairment or Mild Dementia Due to Alzheimer's Disease (Study: E2609-A001-101 Amendment 02) (clinicaltrials.gov) - Sep 23, 2013
P1, N=65, Completed, Sponsor: Eisai Inc.
Not yet recruiting --> Recruiting N=50 --> 65
- ||| elenbecestat (E2609) / Eisai, Biogen
Trial completion: Evaluation of E2609 in Subjects With Mild Cognitive Impairment or Mild Dementia Due to Alzheimer's Disease (Study: E2609-A001-101 Amendment 02) (clinicaltrials.gov) - Sep 23, 2013
P1, N=65, Completed, Sponsor: Eisai Inc.
N=50 --> 65 Terminated --> Completed
- | rivastigmine transdermal / Generic mfg.
Trial initiation date: RIVET: Rivastigmine Patch in Veterans With Cognitive Impairment Following TBI (clinicaltrials.gov) - Sep 22, 2013
P3, N=256, Recruiting, Sponsor: Department of Veterans Affairs
Terminated --> Completed Initiation date: Sep 2012 --> Jan 2013
- | rivastigmine transdermal / Generic mfg.
Enrollment open: RIVET: Rivastigmine Patch in Veterans With Cognitive Impairment Following TBI (clinicaltrials.gov) - Sep 22, 2013
P3, N=256, Recruiting, Sponsor: Department of Veterans Affairs
Initiation date: Sep 2012 --> Jan 2013 Not yet recruiting --> Recruiting
- ||||| rivastigmine / Generic mfg.
New P4 trial: INSTINCT: 16w Interventional Study on Titration and Dose/Efficacy Assessment of Exelon in Chinese Alzheimer's Disease Patients (clinicaltrials.gov) - Sep 22, 2013
P4, N=186, Not yet recruiting, Sponsor: Novartis Pharmaceuticals
- | Trial completion: Therapy for Depressed Elders With Thought Problems (clinicaltrials.gov) - Sep 17, 2013
P3, N=221, Completed, Sponsor: University of California, San Francisco
Not yet recruiting --> Recruiting Active, not recruiting --> Completed
- ||||| New P4 trial: The Feasibility of Florbetapir Quantitation (clinicaltrials.gov) - Sep 17, 2013
P4, N=96, Recruiting, Sponsor: Avid Radiopharmaceuticals
- |||| Enrollment open: The Feasibility of Florbetapir Quantitation (clinicaltrials.gov) - Sep 17, 2013
P4, N=96, Recruiting, Sponsor: Avid Radiopharmaceuticals
Active, not recruiting --> Completed Not yet recruiting --> Recruiting
- Trial completion: Effects of Exercise and Cognitive Training on Cognitive Function in Older Adults (clinicaltrials.gov) - Sep 16, 2013
P=N/A, N=108, Completed, Sponsor: The Cleveland Clinic
Not yet recruiting --> Recruiting Active, not recruiting --> Completed
- | sertraline / Generic mfg.
Trial completion: DIADS-2: Depression in Alzheimer's Disease-2 (clinicaltrials.gov) - Sep 16, 2013
P2/3, N=131, Completed, Sponsor: Johns Hopkins University
Active, not recruiting --> Completed Active, not recruiting --> Completed
- sertraline / Generic mfg.
Trial completion: The Depression in Alzheimer's Disease Study (DIADS) (clinicaltrials.gov) - Sep 16, 2013
P4, N=0, Completed, Sponsor: Johns Hopkins University
Active, not recruiting --> Completed Active, not recruiting --> Completed
- Enrollment change: Cognitive Dysfunction in Fibromyalgia Patients (clinicaltrials.gov) - Sep 15, 2013
P=N/A, N=25, Completed, Sponsor: Hadassah Medical Organization
Active, not recruiting --> Completed N=100 --> 25
- Trial completion: Cognitive Dysfunction in Fibromyalgia Patients (clinicaltrials.gov) - Sep 15, 2013
P=N/A, N=25, Completed, Sponsor: Hadassah Medical Organization
N=100 --> 25 Recruiting --> Completed
- quetiapine extended-release / Generic mfg.
Trial termination: Quetiapine XR for Cognitive and Functional Disability in Clinically Stable Patients With Bipolar Disorder (clinicaltrials.gov) - Sep 12, 2013
P4, N=32, Terminated, Sponsor: Emory University
Recruiting --> Completed Completed --> Terminated; Sponsor withdrew funding
- quetiapine extended-release / Generic mfg.
Enrollment change: Quetiapine XR for Cognitive and Functional Disability in Clinically Stable Patients With Bipolar Disorder (clinicaltrials.gov) - Sep 11, 2013
P4, N=32, Terminated, Sponsor: Emory University
Completed --> Terminated; Sponsor withdrew funding N=100 --> 32
- | bapineuzumab (AAB-001) / Pfizer, J&J, Perrigo Company
Enrollment change: A Long-Term Safety And Tolerability Extension Study Of Bapineuzumab In Alzheimer Disease Patients (clinicaltrials.gov) - Sep 10, 2013
P3, N=493, Terminated, Sponsor: Pfizer
N=100 --> 32 N=410 --> 493
- Enrollment closed: Lipoic Acid and Omega-3 Fatty Acids for Alzheimer's Disease (clinicaltrials.gov) - Sep 9, 2013
P1/2, N=100, Active, not recruiting, Sponsor: Oregon Health and Science University
N=410 --> 493 Recruiting --> Active, not recruiting
- Trial initiation date: PET Imaging Study Using [11C]PIB in Subjects With AD & Healthy Volunteers (clinicaltrials.gov) - Sep 8, 2013
P1, N=30, Recruiting, Sponsor: Dean F. Wong, MD, PhD
Recruiting --> Active, not recruiting Initiation date: May 2013 --> Sep 2013